https://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencySat, 18 May 2024 11:07:26 +0200Mon, 13 May 2024 10:57:00 +0200https://www.ema.europa.eu/en/medicines/human/EPAR/keytrudaHuman medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Date of authorisation: 17/07/2015, Revision: 57, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/keytrudaMon, 13 May 2024 10:57:00 +0200Human medicinehttps://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/p-0096-2023-ema-decision-10-march-2023-granting-product-specific-waiver-pembrolizumab-keytruda-emea-001474-pip03-22Opinion/decision on a Paediatric investigation plan (PIP): Keytruda, Pembrolizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Oncology, PIP number: P/0096/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/p-0096-2023-ema-decision-10-march-2023-granting-product-specific-waiver-pembrolizumab-keytruda-emea-001474-pip03-22Fri, 05 Apr 2024 14:10:35 +0200Human medicinehttps://www.ema.europa.eu/en/medicines/human/variation/keytruda-1Summary of opinion: Keytruda, 22/02/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/keytruda-1Fri, 23 Feb 2024 12:00:00 +0100Human medicinehttps://www.ema.europa.eu/system/files/documents/variation-report/wc500228144_en.pdfKeytruda-H-C-3820-II-0014: EPAR - Assessment Report - Variationhttps://www.ema.europa.eu/system/files/documents/variation-report/wc500228144_en.pdfMon, 22 May 2017 12:04:00 +0200Human medicine